Search - tctmd.com

Displaying 1 - 20 of 127

Sort: Relevancy | Date

Presentation TCT 2025

First Report of the SPYRAL AFFIRM Study: Reduced Home and Office Blood Pressure Following Radiofrequency Renal Denervation in a Large US Cohort of High Cardiovascular Risk Patients.

Presenter: Felix Mahfoud

October 27, 2025

Presentation TCT 2025

On-Table Predictors of Successful Denervation - Where are We in 2025?

Presenter: Felix Mahfoud

October 27, 2025

Presentation TCT 2025

TCT 706: First-in-Human Evaluation of the Zenith Left Atrial Appendage Occlusion System for Stroke Prevention in High-Risk Atrial Fibrillation Patients

Presenter: Felix Mahfoud

October 27, 2025

Presentation TCT 2025

RDN in Global Guidelines

Presenter: Felix Mahfoud

October 27, 2025

Presentation TCT 2025

Case Selection - Picking the Right Patients

Presenter: Felix Mahfoud

October 27, 2025

Presentation TCT 2025

THRIVE Trial in Focus: What the Upcoming Evidence Could Mean

Presenter: Felix Mahfoud

October 26, 2025

Presentation TCT 2025

First-in-Human Evaluation of the Zenith LAAO System for Stroke Prevention in High-Risk Atrial Fibrillation Patients (AuriGen)

Presenter: Felix Mahfoud

October 26, 2025

Presentation TCT 2025

Which Device Should We Choose?

Presenter: Felix Mahfoud

October 26, 2025

Presentation TCT 2024

Editorial Comments

Presenter: Felix Mahfoud

October 29, 2024

Presentation TCT 2024

Safety And Efficacy of Renal Stimulation with Direct Wire Pacing During RDN Procedure: The RNS-DWP Feasibility Study

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Presenter: Felix Mahfoud

October 28, 2024

Presentation TCT 2024

Case Examples and Outcomes

Presenter: Tai Kobayashi

October 28, 2024

Presentation TCT 2024

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

Presenter: Felix Mahfoud

October 28, 2024

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

Presentation TCT 2023

IBERIS Clinical Trial Program (Radio-Frequency Renal Denervation)

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

SYMAP Clinical Trial Program (Radio-Frequency Renal Denervation)

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

PE Risk Stratification in 2023

Presenter: Felix Mahfoud

October 25, 2023

Presentation TCT 2023

Trialist Perspectives

Presenter: Felix Mahfoud

October 24, 2023

Advertisement

First Report of the SPYRAL AFFIRM Study: Reduced Home and Office Blood Pressure Following Radiofrequency Renal Denervation in a Large US Cohort of High Cardiovascular Risk Patients.

On-Table Predictors of Successful Denervation - Where are We in 2025?

TCT 706: First-in-Human Evaluation of the Zenith Left Atrial Appendage Occlusion System for Stroke Prevention in High-Risk Atrial Fibrillation Patients

RDN in Global Guidelines

Case Selection - Picking the Right Patients

THRIVE Trial in Focus: What the Upcoming Evidence Could Mean

First-in-Human Evaluation of the Zenith LAAO System for Stroke Prevention in High-Risk Atrial Fibrillation Patients (AuriGen)

Which Device Should We Choose?

Editorial Comments

Safety And Efficacy of Renal Stimulation with Direct Wire Pacing During RDN Procedure: The RNS-DWP Feasibility Study

TCT 481: Renal Artery Imaging Through Long-Term Follow-Up Following Radiofrequency Renal Denervation: Results From the SPYRAL Clinical Trial Program

TCT 480: Blood Pressure Reductions by Radiofrequency Renal Denervation Procedural Characteristics: Pooled 24-Month Results From the SYMPLICITY Clinical Program

Case Examples and Outcomes

The Body of Evidence: Safety, Efficacy and Sustainability of rf RDN

FDA Approves Paradise Renal Denervation System: What Comes Next?

IBERIS Clinical Trial Program (Radio-Frequency Renal Denervation)

SYMAP Clinical Trial Program (Radio-Frequency Renal Denervation)

TCT 267: Pooled, 12-month Blood Pressure Reductions Using the Symplicity Spyral Radiofrequency Renal Denervation Catheter

PE Risk Stratification in 2023

Trialist Perspectives

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content